Abstract
Introduction
Osteoporosis is a prevalent bone disease that is characterized by loss of bone mass and strength, leading to fragility fracture [1] .
phenomena are known to be achieved by excessive bone resorption and reduced bone formation during bone remodelling, respectively [2] .
Recent progress in stem cell biology has provided a promising strategy for treatment of multiple degenerative disorders [3] . In particular, adult stem cells have emerged as an important issue due to the potential for use of their ex vivo expanded progenies in cell-based regenerative medicine, tissue engineering and cancer therapy [4] . Adult [4] . [5] . Therapeutic potential for bone regeneration by systemic transplantation of genetically manipulated MSCs co-expressing C-X-C chemokine receptor type 4 (CXCR4) and Cbfa-1 in glucocorticoid-induced osteoporotic mice has been recently suggested [6] . [7] . ASCs have also been shown to support differentiation of haematopoietic progenitors into myeloid and B lymphoid cells [8] . ASC-derived cellular therapy has been investigated with respect to a wide variety of human diseases, such as skeletal muscle disorders, cardiovascular disorders and diabetes mellitus, and in bioengineering for tissue regeneration [4] . Additive support of ASCs in tissue repair and regeneration has been reported to include differentiation into a proper cell lineage and paracrine mechanisms mediated by secreted cytokines and growth factors [5] . Growing evidence indicates that paracrine factors play a critical role in ASC-induced tissue repair [9, 10] . Bioactive levels of multiple paracrine factors, including hepatocyte growth factor (HGF), vascular endothelial growth factor, nerve growth factor, insulinlike growth factor-1 (IGF-1), transforming growth factor-␤, basic fibroblast growth factor and granulocyte macrophage colony-stimulating factors are known to be released by ASCs [11] . Moreover, conditioned media obtained from ASCs have been found to protect against cerebellar granule neuron apoptosis [12] .
MSCs obtained from adipose tissues could constitute a promising source of cells for use in cell-based therapy and tissue engineering

The main benefits of adipose-derived stem cells (ASCs) in therapeutic applications, as compared with bone marrowderived MSCs, are that adipose tissue is readily accessible and relatively abundant, and the stem cell population can be easily harvested by simple methods, such as lipoaspiration or surgical resection, and can be rapidly expanded ex vivo
Considering the fact that the pathogenetic mechanisms underlying osteoporosis cover multiple sets of dynamic parameters, a systemic approach using stem cell transplantation is attractive for treatment of osteoporosis. In the present study, we investigated the question of whether systemically transplanted human ASCs (hASCs) could restore bone function and structure in an ovariectomized (OVX)-induced osteoporotic mouse model. (Fig. 1A) . Secretion of RANKL and M-CSF, which are essential for osteoclastogenesis, and HGF, which is known to increase DNA synthesis and proliferation of osteoblasts and osteoclasts [17] , were confirmed in hASC-CM using Western blotting and ELISA ( Fig. 1B and C [18] [19] [20] ; ␤2-microglobulin and thrombospondin-1 are involved in stimulation of osteoclast formation and function [21, 22] 
Materials and methods
Isolation and culture of hASCs
Detection of hASCs after intravenous injection
Results
Characterization of hASCs
Gene and protein expression of bone-related factors in hASCs and mass spectrometric identification of proteins secreted from hASCs
It is well established that hASCs have the ability to secrete a variety of cytokines, including angiogenic, anti-apoptotic and proinflammatory factors [11]. In this study, we examined expression and secretion of bone-related growth factors and cytokines in hASCs. Using RT-PCR, we observed expression of genes encoding HGF, M-CSF, bone morphogenetic protein 2 (BMP-2), BMP-4, osteopontin, RANKL and tumour necrosis factor-␣ in hASCs
Effects of systemic transplantation of hASCs on OVX-induced bone loss
We performed CT analysis to determine the impact of hASCs on OVX-induced osteoporotic mice ( Fig. 2A) [17, 23] were expressed by hASCs (Fig. 1) . Consistently, serum level of human HGF was markedly higher in hASC-transplanted OVX mice than in control OVX mice (Fig. 2E) . Because oestrogen plays a critical role in OVX-induced bone loss [24] , we explored the ovarian and uterine status of recipient mice (Fig. S3) (Fig. 2F) . The effect of hASC-CM on osteoblast and osteoclast differentiation
Our results suggested that hASCs expressed and secreted boneactivating factors into the extracellular space, which are able to potentiate osteoblast and osteoclast differentiation ( Fig. 1 and Table 1 ) [27] , and to play an important role in early osteoblastogenesis [2] . [28] was induced by day 3 after treatment with hASC-CM however, p38 was not affected (Fig. 4F) . (Fig. 5A) Figure 3B , suggesting that hASC-CM could efficiently support osteoclast formation in a manner similar to that of M-CSF. TRAP activity was also higher in osteoclast precursors cultured with hASC-CM than in osteoclast precursors cultured with control medium (Fig. 5C ). mRNA expression of osteoclastic markers, such as cathepsin K, TRAP, NFATc1 and matrix metalloproteinase-9 were induced when osteoclast precursors were cultured in hASC-CM (Fig. 5D ).
. In differentiation of osteoblasts and osteoclasts in vitro, it is established that VitD3 and prostaglandin E2 can lead to osteoblast activation and mineralization and that RANKL, in combination with M-CSF, can induce multinucleated osteoclast formation from a macrophage lineage [14, 25, 26]. Thus, we assessed a stimulatory action of hASC-derived secreted factors in osteoblast and osteoclast differentiation under various combined cultures of bone cell-stimulating factors, hASCs-CM and HEK293T-CM as a control. Among various combinations, osteoblast cultures with hASC-CM and VitD3 displayed mineral deposition, but did not with HEK293T-CM and VitD3 (Fig. 3A). In additional, combined treatment of hASC-CM-and RANKL-induced differentiation of osteoclast precursors into TRAP ϩ multinucleated cells (MNCs), whereas HEK293T-CM and RANKL treatment failed to induce their differentiation (Fig. 3B). These results indicate that osteoblastogenic factors present in hASC-CM can be substituted for prostaglandin E2, and that osteoclastogenic factors in hASC-CM can be substituted for M-CSF.
Stimulatory effect of hASC-CM on osteoblast proliferation and differentiation
Compared with sham-operated and OVX mice, systemic transplantation of hASCs into OVX mice resulted in an increase in the number of osteoblasts and osteoclasts on bone surfaces (Fig. 2D). To elucidate the molecular mechanisms responsible for in vivo results, we investigated the question of whether hASC-CM could affect the physiological properties of osteoblasts, including proliferation, adhesion, spreading and differentiation. We found that hASC-CM induced an increase in the osteoblast population, compared with the control medium (Fig. 4A). We also found that hASC-CM markedly promoted cell attachment and spreading, compared with the control medium (Fig. 4B and C). These enhanced activities of cell attachment and spreading were completely inhibited by EDTA, but not by heparin, suggesting that cell attachment and spreading in osteoblasts might be promoted by hASC-CM through a divalent cation-dependent mechanism. Whereas cultures supplemented with either hASC-CM or VitD3 alone did not induce matrix mineralization of osteoblasts, addition of both hASC-CM and VitD3 to cultures accelerated the mineralization of osteoblasts (Fig. 4D). We next examined the effects of hASC-CM on signalling events in osteoblasts. As shown in Figure 4E, short-term treatment of osteoblasts with hASC-CM resulted in increased phosphorylation of receptor-regulated Smad 1/5/8, which is known to function as an intracellular mediator of osteoblast differentiation signalling
However, neither phosphorylation nor expression levels of ␤-catenin in osteoblasts were altered by treatment with hASC-CM. In addition, we measured the activities of three MAPKs, ERK, c-jun NH2-terminal kinase (JNK) and p38 in osteoblasts after long-term treatment with hASC-CM. Maximal activation of both ERK and JNK, which can, in part, stimulate osteoblast differentiation
Stimulatory effect of hASC-CM on osteoclast precursor survival and osteoclast differentiation
The combination of M-CSF and RANKL is indispensable for both survival and differentiation of osteoclast precursors [14]. To evaluate the effect of hASC-CM on survival and proliferation of osteoclast precursors, we counted the numbers of osteoclast precursors after exposure to hASC-CM. The number of osteoclast precursors cultured with hASC-CM was considerably higher than that of osteoclast precursors cultured with control medium
All three major subfamilies of MAPKs, ERK, JNK and p38, which are known to play an important role in osteoclastogenesis, were activated immediately after hASC-CM treatment in osteoclast precursors (Fig. 5E). In contrast to the stimulatory action of hASC-CM in osteoblast adhesion and spreading (Fig. 4B and C), hASC-CM did not affect adhesion and spreading of osteoclast precursors (data not shown).
Discussion
Bioactive trophic factors secreted by ASCs have been reported to directly contribute to angiogenic and anti-apoptotic effects in ischemic limb disease, restoration of heart function and nerve
sprouting following myocardial infarction, and skin wound healing [9, 10, 29, 30] . In this study, we showed that hASC-based therapy via systemic transplantation could be effective in bone repair by a mechanism predominantly mediated through secretion of paracrine factors by hASCs. Osteoporosis is a chronic and complex disease involving an uncoupling between bone formation and bone resorption. Multiple pathogenetic mechanisms are involved in loss of bone mass and microarchitectural reduction of bone tissue in osteoporosis [1] . Bone repair is known to be a complex physiologic process that is regulated by several cell types, as well as the extracellular matrix and growth factors [31] . Secretion of important growth factors with potential for mediation of bone repair, including vascular endothelial growth factor, IGF-1 and TGF-␤ [32] from ASCs has been demonstrated [11] . Stem cell homing capacity to the site of tissue injury is important for effective stem cell therapy. When hASCs labelled with Qtracker-delivered quantum dots were injected into OVX mice on post-operative day 28, a quantum dot signal could not be detected in bone at 60 min. after injection (Fig. S4A) . A control experiment was performed with an experimental ischemia model in rat kidney to evaluate our system for assessment of the distribution of hASCs. Intense fluorescence from Qtracker labels and ironlabelled cells could be clearly seen at the ischemic site after injection of quantum-dot labelled or iron-labelled hASCs into ischemic kidney rats via tail vein (Fig. S4B and C Synthesis of VitD3 has been reported to occur in bone cells [34] , and stimulation of osteoblast matrix mineralization by HGF in concert with VitD3 has also been reported [35] . Our study showed that hASC-CM together with VitD3-induced mineralization of [8] . Involvement of ERK in osteoclast survival has been reported [38] , and involvement of p38 and JNI in osteoclast differentiation has also been reported [39, 40] 
cells per well in 24-well plates) using a control medium (50% DMEM in ␣-MEM) or hASC-CM (50% hASC-CM in ␣-MEM) for the indicated times, trypan blue-excluded cells were counted using a haemocytometer under a light microscope. Data represent mean Ϯ S.D. (n ϭ 3). Cell adhesion (B) and spreading (C) assays were performed on osteoblasts incubated for 1 hr in the same media as in (A
